Nifty
:
17331.80
Sensex
:
58222.10
57.50 (0.33%)
156.63 (0.27%)
Nifty
Sensex
:
:
17331.80
58222.10
57.50 (0.33%)
156.63 (0.27%)

Shilpa Medicare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
33/99

BSE: 530549 | NSE: SHILPAMED

NSE BSE
365.15
06-Oct-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 379.30
  • 387.50
  • 364.30
  • 376.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  365237
  •  1360.66
  •  658.00
  •  355.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,168.27
  • 52.80
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,816.07
  • 0.30%
  • 1.73

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.01%
  • 12.21%
  • 20.51%
  • FII
  • DII
  • Others
  • 14.41%
  • 1.01%
  • 1.85%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.92
  • 7.75
  • 8.06

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.96
  • 5.45
  • -1.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.51
  • -11.61
  • -27.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 35.77
  • 27.55
  • 26.77

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.99
  • 2.79
  • 2.49

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.75
  • 19.95
  • 20.59

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Net Sales
261.16
237.36
10.03%
340.59
208.03
63.72%
272.30
191.25
42.38%
295.27
278.94
5.85%
Expenses
240.59
205.48
17.09%
266.87
181.82
46.78%
227.21
170.28
33.43%
242.11
210.25
15.15%
EBITDA
20.57
31.88
-35.48%
73.73
26.21
181.30%
45.09
20.97
115.02%
53.16
68.68
-22.60%
EBIDTM
7.88%
13.43%
21.65%
12.60%
16.56%
10.96%
18.00%
24.62%
Other Income
8.10
1.99
307.04%
5.49
6.91
-20.55%
5.48
8.61
-36.35%
1.28
9.20
-86.09%
Interest
9.59
10.32
-7.07%
9.35
9.12
2.52%
9.92
4.80
106.67%
11.58
3.95
193.16%
Depreciation
22.42
17.63
27.17%
22.34
15.23
46.68%
20.65
13.72
50.51%
19.18
12.70
51.02%
PBT
-3.34
5.92
-
47.41
8.76
441.21%
20.00
11.05
81.00%
32.59
61.23
-46.77%
Tax
-6.41
3.56
-
16.86
0.80
2,007.50%
9.71
2.92
232.53%
11.56
15.99
-27.70%
PAT
3.08
2.36
30.51%
30.55
7.96
283.79%
10.29
8.14
26.41%
21.03
45.24
-53.51%
PATM
1.18%
1.00%
8.97%
3.83%
3.78%
4.25%
7.12%
16.22%
EPS
0.10
0.19
-47.37%
3.40
0.96
254.17%
1.10
0.94
17.02%
2.45
5.57
-56.01%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
1,169.32
1,145.52
901.13
907.91
733.39
788.83
779.16
716.43
613.80
571.38
371.32
Net Sales Growth
27.71%
27.12%
-0.75%
23.80%
-7.03%
1.24%
8.76%
16.72%
7.42%
53.88%
 
Cost Of Goods Sold
411.21
383.22
270.73
277.73
257.03
355.87
371.81
366.19
323.16
313.26
213.95
Gross Profit
758.11
762.30
630.40
630.18
476.36
432.95
407.36
350.25
290.63
258.12
157.38
GP Margin
64.83%
66.55%
69.96%
69.41%
64.95%
54.89%
52.28%
48.89%
47.35%
45.17%
42.38%
Total Expenditure
976.78
948.32
729.43
693.39
579.39
637.60
617.55
556.44
487.38
455.40
301.63
Power & Fuel Cost
-
52.43
40.25
38.76
33.57
28.86
26.30
21.90
19.29
17.37
10.67
% Of Sales
-
4.58%
4.47%
4.27%
4.58%
3.66%
3.38%
3.06%
3.14%
3.04%
2.87%
Employee Cost
-
264.49
235.31
196.59
176.40
149.35
127.87
90.09
82.30
67.83
42.56
% Of Sales
-
23.09%
26.11%
21.65%
24.05%
18.93%
16.41%
12.57%
13.41%
11.87%
11.46%
Manufacturing Exp.
-
124.11
91.29
79.19
61.23
59.96
52.55
45.35
36.55
27.44
16.92
% Of Sales
-
10.83%
10.13%
8.72%
8.35%
7.60%
6.74%
6.33%
5.95%
4.80%
4.56%
General & Admin Exp.
-
71.58
47.71
70.26
27.20
22.50
16.95
14.11
10.64
9.53
9.51
% Of Sales
-
6.25%
5.29%
7.74%
3.71%
2.85%
2.18%
1.97%
1.73%
1.67%
2.56%
Selling & Distn. Exp.
-
25.29
18.63
10.40
6.72
6.37
4.75
7.27
5.99
7.29
4.43
% Of Sales
-
2.21%
2.07%
1.15%
0.92%
0.81%
0.61%
1.01%
0.98%
1.28%
1.19%
Miscellaneous Exp.
-
27.22
25.51
20.47
17.23
14.68
17.32
11.54
9.45
12.68
4.43
% Of Sales
-
2.38%
2.83%
2.25%
2.35%
1.86%
2.22%
1.61%
1.54%
2.22%
0.97%
EBITDA
192.55
197.20
171.70
214.52
154.00
151.23
161.61
159.99
126.42
115.98
69.69
EBITDA Margin
16.47%
17.21%
19.05%
23.63%
21.00%
19.17%
20.74%
22.33%
20.60%
20.30%
18.77%
Other Income
20.35
20.90
40.09
22.22
15.56
32.62
29.34
11.36
6.93
9.12
5.01
Interest
40.44
41.17
21.87
4.56
3.68
2.66
3.13
3.93
4.05
3.52
2.27
Depreciation
84.59
79.80
53.98
43.78
42.06
37.22
30.64
23.14
21.41
23.22
15.34
PBT
96.66
97.13
135.95
188.40
123.82
143.96
157.17
144.28
107.89
98.35
57.10
Tax
31.72
41.68
48.85
33.49
26.18
33.91
42.04
35.62
35.22
20.30
9.53
Tax Rate
32.82%
39.35%
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
32.66%
21.27%
16.72%
PAT
64.95
60.66
147.78
156.50
120.28
112.43
113.71
109.84
73.69
75.67
47.35
PAT before Minority Interest
63.56
60.58
146.20
154.91
117.52
110.05
110.59
106.24
72.62
75.15
47.47
Minority Interest
-1.39
0.08
1.58
1.59
2.76
2.38
3.12
3.60
1.07
0.52
-0.12
PAT Margin
5.55%
5.30%
16.40%
17.24%
16.40%
14.25%
14.59%
15.33%
12.01%
13.24%
12.75%
PAT Growth
1.96%
-58.95%
-5.57%
30.11%
6.98%
-1.13%
3.52%
49.06%
-2.62%
59.81%
 
EPS
7.48
6.99
17.03
18.03
13.86
12.95
13.10
12.65
8.49
8.72
5.46

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
1,822.19
1,478.67
1,329.36
1,197.58
1,085.03
986.90
639.26
546.94
396.45
320.42
Share Capital
8.68
8.15
8.15
8.15
8.15
8.01
7.71
7.71
7.36
4.90
Total Reserves
1,813.51
1,470.51
1,321.21
1,189.43
1,076.88
978.88
631.55
539.23
389.09
315.52
Non-Current Liabilities
452.82
561.37
256.94
166.62
153.48
251.26
67.23
154.15
104.53
98.51
Secured Loans
353.49
473.87
164.48
80.39
67.09
141.20
0.03
71.03
37.43
70.47
Unsecured Loans
0.11
0.35
0.53
0.70
1.03
1.30
0.00
31.30
30.05
0.00
Long Term Provisions
19.08
15.48
26.17
21.77
20.32
16.89
13.96
11.75
9.93
6.92
Current Liabilities
611.54
543.29
410.82
253.44
265.84
236.90
222.07
189.06
166.84
123.77
Trade Payables
146.04
67.25
92.55
80.72
103.74
111.86
106.48
75.50
92.98
51.26
Other Current Liabilities
240.13
219.33
142.10
81.62
59.59
28.03
36.49
49.32
38.23
23.38
Short Term Borrowings
202.90
243.40
165.27
86.58
98.12
92.41
74.10
58.47
30.27
45.07
Short Term Provisions
22.46
13.31
10.89
4.52
4.39
4.60
5.00
5.77
5.37
4.06
Total Liabilities
2,875.50
2,572.16
1,989.21
1,610.02
1,499.13
1,472.22
930.89
904.54
677.83
551.42
Net Block
1,341.84
1,110.53
650.44
558.01
534.20
491.93
393.41
316.06
294.42
180.67
Gross Block
1,725.77
1,421.10
986.42
853.16
793.24
704.89
582.20
476.34
448.38
300.89
Accumulated Depreciation
383.93
310.57
335.98
295.15
259.04
212.96
188.79
160.28
153.96
120.22
Non Current Assets
1,988.30
1,729.60
1,365.35
1,064.96
827.16
742.33
576.68
576.77
443.89
339.18
Capital Work in Progress
506.18
541.29
666.25
429.12
209.85
140.51
91.90
221.62
111.03
129.15
Non Current Investment
34.23
21.22
10.45
2.25
20.79
27.99
34.15
0.19
0.21
0.14
Long Term Loans & Adv.
93.90
43.10
32.42
48.75
37.47
77.09
51.86
38.74
38.18
28.82
Other Non Current Assets
12.15
13.46
5.78
26.84
24.86
4.80
5.36
0.16
0.06
0.40
Current Assets
887.19
818.99
623.85
545.06
671.97
729.88
354.21
327.61
233.74
211.99
Current Investments
0.00
0.00
0.00
0.00
119.54
224.62
59.63
65.35
10.14
50.28
Inventories
355.24
316.84
226.43
187.67
188.71
190.00
134.23
130.78
123.25
74.33
Sundry Debtors
386.33
217.50
246.79
203.73
220.27
170.93
125.43
81.37
67.96
41.79
Cash & Bank
34.11
123.11
44.56
94.54
73.83
100.39
11.03
18.42
9.19
16.87
Other Current Assets
111.52
98.73
76.81
45.04
69.62
43.95
23.90
31.69
23.20
28.72
Short Term Loans & Adv.
37.04
62.81
29.25
14.08
43.54
21.95
8.90
4.91
3.23
2.86
Net Current Assets
275.66
275.69
213.04
291.62
406.13
492.98
132.14
138.55
66.90
88.22
Total Assets
2,875.49
2,548.59
1,989.20
1,610.02
1,499.13
1,472.21
930.89
904.54
677.83
551.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
105.13
46.93
124.38
146.78
44.92
37.48
128.70
68.81
70.04
43.64
PBT
105.93
196.79
188.40
143.70
136.77
146.49
140.36
107.84
95.45
57.00
Adjustment
105.68
4.03
41.32
20.44
18.83
17.19
20.61
26.46
19.62
11.52
Changes in Working Capital
-71.99
-106.29
-63.15
18.71
-69.66
-92.61
-2.70
-40.11
-23.44
-13.90
Cash after chg. in Working capital
139.62
94.53
166.57
182.85
85.94
71.08
158.27
94.19
91.62
54.62
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-34.48
-47.60
-42.20
-36.07
-41.02
-33.60
-29.56
-25.38
-21.58
-10.98
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-285.50
-404.28
-289.52
-196.16
-8.76
-262.23
-109.20
-195.18
-48.93
-95.21
Net Fixed Assets
385.38
-272.02
-4.28
-256.96
-136.75
-172.23
-92.14
-78.46
-61.02
-83.52
Net Investments
-18.18
-125.84
-4.44
141.85
95.51
-172.72
-14.09
-64.38
12.08
13.84
Others
-652.70
-6.42
-280.80
-81.05
32.48
82.72
-2.97
-52.34
0.01
-25.53
Cash from Financing Activity
82.86
436.37
175.50
10.06
-60.91
312.70
-19.65
135.05
-28.34
66.31
Net Cash Inflow / Outflow
-97.51
79.03
10.36
-39.32
-24.75
87.95
-0.15
8.68
-7.23
14.74
Opening Cash & Equivalents
122.85
44.31
34.13
73.83
99.97
7.05
3.61
9.19
16.87
2.27
Closing Cash & Equivalent
25.34
123.34
44.31
34.36
73.83
99.97
6.43
18.42
9.19
16.87

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
209.93
181.37
163.06
146.89
133.09
123.17
82.91
70.92
107.72
43.52
ROA
2.20%
6.33%
8.61%
7.56%
7.41%
9.20%
11.58%
9.18%
12.23%
9.64%
ROE
3.67%
10.41%
12.26%
10.30%
10.62%
13.60%
17.92%
15.40%
20.98%
15.93%
ROCE
5.94%
10.73%
12.41%
11.05%
11.71%
15.91%
19.90%
17.90%
20.48%
15.04%
Fixed Asset Turnover
0.73
0.75
0.99
0.89
1.06
1.22
1.36
1.34
1.54
1.32
Receivable days
96.20
94.03
90.56
105.51
90.20
69.00
52.26
43.99
34.62
39.70
Inventory Days
107.07
110.03
83.24
93.66
87.32
75.49
66.97
74.84
62.33
68.31
Payable days
101.58
107.72
47.69
58.00
61.51
60.89
60.10
62.86
57.06
63.94
Cash Conversion Cycle
101.69
96.33
126.11
141.17
116.00
83.61
59.13
55.97
39.90
44.07
Total Debt/Equity
0.37
0.57
0.29
0.16
0.18
0.24
0.14
0.34
0.30
0.41
Interest Cover
3.48
9.92
42.34
40.09
55.10
49.69
37.07
27.63
28.09
26.13

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Shilpa Medicare’s Analytical Services division gets USFDA’s clearance
    22nd Sep 2022, 17:26 PM

    The FDA clearance on the facility will enable the company to test and release batches into US from this facility

    Read More
  • Shilpa Medicare gets CDSCO approval for hemostatic spray of Tranexamic Acid
    20th Sep 2022, 12:16 PM

    The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038

    Read More
  • Shilpa Medicare gets USFDA’s nod for Tenofovir Alafenamide tablets
    16th Sep 2022, 14:29 PM

    The US market for Tenofovir Alafenamide Tablets, 25 mg is around $498.14 million

    Read More
  • Shilpa Medicare’s arm completes Human Clinical studies of High concentration Biosimilar Adalimumab
    19th Aug 2022, 16:00 PM

    The company has submitted the dossier to the CDSCO for review and grant of marketing/manufacturing license - a first in India

    Read More
  • Shilpa Medicare - Quarterly Results
    11th Aug 2022, 18:46 PM

    Read More
  • Shilpa Medicare’s Bengaluru unit clears USFDA remote record review
    29th Jul 2022, 16:42 PM

    The facility is designed with advanced analytical equipment to provide testing services

    Read More
  • Shilpa Medicare gets GMP certificate from MOH-Russia for API facility in Karnataka
    18th Jul 2022, 10:01 AM

    The facility involves in manufacturing, testing, packing, storage of chemically synthesized nonsterile drug substances for human use

    Read More
  • Shilpa Medicare gets GMP Certificate from UK MHRA for Bengaluru facility
    12th Jul 2022, 16:57 PM

    The facility was inspected by MHRA from April 18, 2022 to April 20, 2022

    Read More
  • Shilpa Medicare executes transfer agreement with Shilpa Pharma Lifesciences
    4th Jul 2022, 09:22 AM

    With effect from closing of the transaction, Shilpa Pharma Lifesciences, a wholly owned subsidiary of Shilpa Medicare shall operate the API business

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.